# A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

> **NCT02238782** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21 (actual)

## Conditions studied

- Healthy Volunteers Bioavailability Study

## Interventions

- **DRUG:** selumetinib 75mg single dose
- **OTHER:** [14C] selumetinib IV solution

## Key facts

- **NCT ID:** NCT02238782
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2014-11
- **Final completion:** 2014-11
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2016-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02238782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02238782, "A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02238782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*